Jean Armengaud – Microbial Proteomics

Jean Armengaud, PhD is best known for his work on proteogenomics of bacteria and the characterization of pathogens. He is the scientific director of a mass spectrometry research unit located near Avignon in France that is dedicated to proteomics-based identification and quantitation of pathogens and environmentally relevant microorganisms. His research group is developing new tools and concepts for metaproteomics and the taxonomical and functional characterization of complex microbiota.

Tiziana Bonaldi – Systems Biology

TB is Tenured Group Leader at the European Institute of Oncology (IEO) in Milan, where she directs the “Cacner epi- proteomics and gene expression regulation” since 2008. Following a PhD in Molecular and Cellular Biology at the Dibit, San Raffaele Institute in Milan, she did a first post-doc at the LMU in Munich, in A. Imhof’s lab, where she started developing MS methods to study the histone code; then she carried out a second post-doc in the M- Mann’s group at the MPI of Biochemistry in Martinsried to strengthen her expertise in quantitative proteomics. She received the “Armenise-Harvard Career Development Award” in 2007 and the “International Inner Wheel for Women, for scientific achievements” in 2010. In 2014, she successfully completed her tenure-track and was appointed as Associate Professor at IEO. TB group effort is devoted to conjugating mass spectrometry (MS) –based proteomics to the investigation of the molecular mechanisms underpinning adaptive response in cancer, linked to epigenetic regulation of gene expression. Her research has contributed both technological innovations and original findings in MS-analysis of chromatin composition and modifications, on histones and beyond. She published 75 peer-review scientific papers (Google scholar h-index= 35).She’s married, with 2 children

Sarah Cianferani – Interactomics

Dr. Sarah CIANFERANI is a research Director at the National Center for Scientific Research (CNRS) in France. She is currently heading the BioOrganic Mass Spectrometry Laboratory at the Institut Pluridisciplinaire Hubert Curien (IPHC) in Strasbourg, a team of 40 people that has strong expertise in proteomic analyses and structural mass spectrometry. Her expertise focuses on developments in structural mass spectrometry and applications of advanced native mass spectrometry and native ion-mobility mass spectrometry methodologies for biological noncovalent complex characterization, and especially biopharmaceuticals.  Dr. Sarah Cianférani holds a PhD degree in analytical chemistry from the University of Strasbourg, France. She performed and post-doctoral fellowship at the Institute for Genetics and Molecular Biology (IGBMC) in Strasbourg to gain expertise in structural biology. She then joined the AliX company to develop native Mass Spectrometry for protein/ligand screening. She was recruited by the CNRS as researcher in 2004 in the team of Alain Van Dorsselaer (BioOrganic Mass Spectrometry Lab, LSMBO) in Strasbourg. She is now research director at the CNRS and heads the BioOrganic Mass Spectrometry Laboratory (LSMBO). Her group is part of the French National Proteomic Infrastructure. She is co-author of more than 180 scientific papers related to mass spectrometry analysis of proteins.

Pedro R. Cutillas – Proteomics in Cell Biology

My research group uses unique proteomics and computational approaches to understand how cell signalling pathways driven by the activity of protein kinases contribute to the development of cancer. Increasing this knowledge will be invaluable in advancing personalised cancer therapies. I graduated with a PhD in 2004 from UCL, UK. My studies (completed in the laboratories of Prof Mike Waterfield, Prof Rainer Cramer and Prof Al Burlingame) were on a project that investigated kidney physiology and were supervised by Prof Robert Unwin. I then completed postdoctoral training at the Ludwig Institute for Cancer Research (UCL branch) in Bart Vanhaesebroeck’s lab. In 2007, I obtained a lectureship at the Centre for Cell Signalling. After a period in the MRC Clinical Sciences Centre (2012-2013), where I was Head of the Mass Spectrometry and Proteomics, I joined the Centre for Haemoto-Oncology in 2013 where I now lead the Cell Signalling and Proteomics Group.

Jesús Jorrín – Proteomics of Plants, Animals, and Agrobiotechnology

Ph D in Biology at the University of Córdoba (1986), Professor at the Department of Biochemistry and Molecular Biology, University of Córdoba, and Head of the Agroforestry and Plant Biochemistry, Proteomics, and Systems Biology Research Group (AGR-164; With a professional life of 36 years, joined the University as undergraduate student by 1975. My main interest and research are Plant Biology, mostly focused on crops and, lately, forest tree species. By using a molecular approach, including classic biochemistry and -omics techniques I pretended to deep in the knowledge of plant developmental and responses to environmental stresses, trying to understand biodiversity. I have tried follow what I do understand is the main mission of the University, to connect the research and the academy, and offer to undergraduate, master, and Ph. D. students the possibility of an active participation in research projects as a mean of being trained and educated in science. This without forgetting the translation to the productive sectors and to the society. Back by the mid and latte’s 2000 he took an active part in the creation of the SEProt and the EuPA, always trying to promote proteomics research in the plant science field.

Manuel Mayr – Clinical Proteomics

Manuel Mayr qualified in Medicine from the University of Innsbruck (Austria) in 1999.  He then moved to London to undertake a PhD on combining proteomics and metabolomics. Upon completion of his PhD, he achieved promotion to Professor at King’s College London in 2011. In 2017, he has been awarded a British Heart Foundation Personal Chair for Cardiovascular Proteomics. His academic achievements have been recognised by the inaugural Michael Davies Early Career Award of the British Cardiovascular Society (2007), the inaugural Bernard and Joan Marshall Research Excellence Prize of the British Society for Cardiovascular Research (2010), and the Outstanding Achievement Award by the European Society of Cardiology Council for Basic Cardiovascular Science (2013).

Liam McDonnell – Standarization and Emerging Tech.

Liam McDonnell, PhD, leads the Proteomics & Metabolomics laboratory of the Fondazione Pisana per la Scienza ONLUS (Pisa, Italy) and is also Associate Professor at Leiden University Medical Center (Leiden, the Netherlands). He is President of the Mass Spectrometry Imaging Society. He has extensive experience in the clinical application of mass spectrometry imaging, with a special focus on using it to go beyond normal histopathological analysis and to investigate neurological disorders that lack clear histopathological features. In recent years he has focused on the interface of mass spectrometry imaging with ultra high sensitivity proteomics, in which mass spectrometry imaging is first used to define regions-of-interest, which are then isolated and analyzed by LC-MS/MS.

Julio Saez-Rodríguez – Bioinformatics

Julio Saez-Rodriguez is Professor of Medical Bioinformatics and Data Analysis at the Faculty of Medicine of the University of Heidelberg, and director of the institute of computational biomedicine. He is also a group leader of the EMBL-Heidelberg University Molecular Medicine Partnership Unit. and a co-director of the DREAM challenges ( to crowdsource computational systems biology. He obtained his M.S. in Chemical Engineering in 2001 from the University of Oviedo, and a PhD in 2007 at the University of Magdeburg and the Max-Planck-Institute. He was a postdoctoral fellow at Harvard Medical School and M.I.T., and a Scientific Coordinator of the NIH-NIGMS Cell Decision Process Center from 2007 to 2010. From 2010 until 2015 he was a group leader at EMBL-EBI with a joint appointment in the EMBL Genome Biology Unit in Heidelberg, as well as a senior fellow at Wolfson College (Cambridge). From 2015 to 2018 he was professor of Computational Biomedicine at the RWTH University Medical Hospital in Aachen, Germany. He is interested in developing and applying computational methods to acquire a functional understanding of signaling networks and their deregulation in disease, and to apply this knowledge to develop novel therapeutics. Current emphasis in his group is on use of single-cell technologies, multi-omics integration, and understanding multi-cellular communication. While his previous focus has been on cancer, he is increasingly working on autoimmune, kidney and cardiovascular disease. More information at